Galantamine for Cognitive Dysfunction

This study will examine whether galantamine, a drug approved by the Food and Drug Administration to reduce cognitive impairments in people with Alzheimer's disease, can perform the same function in stable people with bipolar disorder. This research study examines the effectiveness of galantamine compared to placebo (contains no active medication) in the treatment of bipolar patients who complain of everyday memory or attention difficulties. In this study, patients will receive either galantamine or placebo for four months at no cost. Participation in this research study is expected to last 18 weeks and includes six outpatient visits, which are approximately 1.5 hours each, and three hours for the screening (and exit visits). Subjects will be reimbursed $50 for the baseline and exit visits and $25 for all other visits. Volunteers may be eligible for this study if they are between the ages of 18 and 65, have a diagnosis of bipolar disorder I or II, and are currently not experiencing a mood episode of depression or mania.

Contact Information:
Principle Investigator: Dan V. Iosifescu
Study Coordinator: Katie Huryk
Tel: 212-241-3089
E-mail: kathryn.huryk@mssm.edu

Recruiting patients: Yes

Address:
Atran Berg Laboratory Building
Floor E Level
1428 Madison Avenue
New York, NY 10029